Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results from the global burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–91.
Article PubMed PubMed Central Google Scholar
Teng YX, Xie S, Guo PP, Deng ZJ, Zhang ZY, Gao W, et al. Hepatocellular Carcinoma in non-alcoholic fatty liver disease: current progresses and challenges. J Clin Transl Hepatol. 2022;10(5):955–64.
Article PubMed PubMed Central Google Scholar
Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022;34(7):969–e772.
Article CAS PubMed PubMed Central Google Scholar
Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30.
Su JY, Deng ZJ, Teng YX, Koh YX, Zhang WG, Zheng MH et al. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis. BJS Open. 2023;7(1):zrac167.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.
Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven proposed nomenclature for metabolic Associated fatty liver disease. Gastroenterology. 2020;158(7):1999–e20141.
Article CAS PubMed Google Scholar
Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–14.
Article CAS PubMed Google Scholar
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64.
Liu L, Xie S, Teng YX, Deng ZJ, Chen K, Liu HT, et al. Outcomes of Liver Resection for Metabolic Dysfunction-Associated fatty liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol. 2021;11:783339.
Article CAS PubMed Google Scholar
Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001–12.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver diseases. Hepatology. 2018;67(1):328–57.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.
Article CAS PubMed Google Scholar
[Chinese guidelines for lipid management. (2023)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023;51(3):221– 55.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
Rolland B, Chazeron I, Carpentier F, Moustafa F, Viallon A, Jacob X, et al. Comparison between the WHO and NIAAA criteria for binge drinking on drinking features and alcohol-related aftermaths: results from a cross-sectional study among eight emergency wards in France. Drug Alcohol Depend. 2017;175:92–8.
Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55(6):1809–19.
Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–30.
Article PubMed PubMed Central Google Scholar
Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–88.
Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38.
Joseph CA, Yi-Te L, Vatche GA, Yazhen Z, Sungyong Y, Hsian-Rong T, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10.
Eliza WB, Leva G, Jaclyn V, Lindsey S, Ann Scheck M, Allan T. Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers’ perspectives. Hepatoma Res. 2023;9:45.
Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol. 2022;37(5):782–94.
Article CAS PubMed Google Scholar
Pan LX, Wang YY, Li ZH, Luo JX, Wu KJ, Liu ZX, et al. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial. Trials. 2024;25(1):25.
Article CAS PubMed PubMed Central Google Scholar
Wang QX, Xue J, Shi MJ, Xie YB, Xiao HM, Li S, et al. Association between Metabolic Dysfunction-Associated fatty liver Disease and the risk of cirrhosis in patients with chronic Hepatitis B-A Retrospective Cohort Study. Diabetes Metab Syndr Obes. 2022;15:2311–22.
Article CAS PubMed PubMed Central Google Scholar
Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and Alcohol-Associated Liver Disease Will be responsible for almost all New diagnoses of cirrhosis in Canada by 2040. Hepatology. 2021;74(6):3330–44.
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–83.
Article CAS PubMed Google Scholar
Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C Virus infection is Associated with increased Cardiovascular Mortality: a Meta-analysis of Observational studies. Gastroenterology. 2016;150(1):145–55..e4; quiz e15-6.
Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, et al. Prevalence and treatment of diabetes in China, 2013–2018. JAMA. 2021;326(24):2498–506.
Article PubMed PubMed Central Google Scholar
Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with Diabetes, chronic kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. J Clin Endocrinol Metab. 2022;107(1):88–97.
Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69–78.
Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic manifestations. J Clin Transl Hepatol. 2019;7(2):172–82.
PubMed PubMed Central Google Scholar
Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65(9):1391–8.
Article CAS PubMed Google Scholar
Xuan Y, Gao P, Shen Y, Wang S, Gu X, Tang D, et al. Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population. Horm (Athens). 2022;21(3):437–46.
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.
Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular Risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290–9.
Article CAS PubMed Google Scholar
Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-Associated fatty liver Disease and Incident Cardiovascular Disease Risk: a Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19(10):2138–e4710.
Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–32.
Article CAS PubMed PubMed Central Google Scholar
Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.
留言 (0)